NurExone Biologic Invited to Present at Key Conferences
NurExone Biologic Inc. (TSXV: NRX), (OTCQB: NRXBF), (Germany: J90) is thrilled to share that its Chief Executive Officer, Dr. Lior Shaltiel, has received invitations to present at several prestigious upcoming conferences. This recognition highlights the Company's dedication to advancing exosome research for clinical applications and regenerative medicine.
ExoPTEN Therapy Presentation
During his presentation, Dr. Shaltiel will showcase NurExone's groundbreaking ExoPTEN nanodrug, which holds promise as a potential treatment for acute spinal cord injuries and various central nervous system disorders, including glaucoma. His talk will focus on "A Comparative Analysis of AbbVie and NurExone's Approaches to Effective Spinal Cord Injury Treatment." This conference is a key event in the bioprocessing and manufacturing sector, providing opportunities to engage with industry leaders, researchers, and potential collaborators.
Participation Details
In addition to the Bioprocess International Conference, Dr. Shaltiel is also set to be a panelist at the Pioneering Israel Medicine Conference. He will share valuable insights about NurExone's pioneering work in exosomes for regenerative medicine. Notably, this event will also feature the esteemed Nobel Prize Laureate Professor Aaron Ciechanover, adding to the event's significance.
Significance of Exosome Technologies
Dr. Shaltiel's participation in these influential conferences underscores NurExone's growing presence and impact in the regenerative medicine field. The research and innovations presented are expected to resonate with many stakeholders eager to learn about advancements in exosome technologies.
About NurExone Biologic Inc.
NurExone Biologic Inc. is a pharmaceutical company listed on the TSX Venture Exchange (TSXV) and OTCQB, dedicated to developing biologically-guided exosome-based therapies aimed at helping patients with central nervous system injuries. The Company's flagship product, ExoPTEN, has demonstrated remarkable efficacy, recovering motor functions in 75% of laboratory rats when administered intranasally. Additionally, the product has received Orphan Drug Designation from the FDA, highlighting its potential therapeutic benefits.
Innovative Drug Delivery Solutions
NurExone's platform technology is expected to introduce innovative solutions for pharmaceutical companies interested in non-invasive drug delivery systems. With a strong emphasis on safety and efficacy, the advancements in exosome technology open new pathways for treating a variety of medical conditions.
Contact Information
For further information or inquiries, please contact:
Dr. Lior Shaltiel
Chief Executive Officer and Director
Phone: +972-52-4803034
Email: info@nurexone.com
Thesis Capital Inc.
Investor Relations - Canada
Phone: +1 905-347-5569
Email: IR@nurexone.com
Dr. Eva Reuter
Investor Relations - Germany
Phone: +49-69-1532-5857
Email: e.reuter@dr-reuter.eu
Allele Capital Partners
Investor Relations - US
Phone: +1 978-857-5075
Email: aeriksen@allelecapital.com
Frequently Asked Questions
What is NurExone Biologic known for?
NurExone Biologic specializes in developing exosome-based therapies, particularly focusing on treating central nervous system injuries.
Who is Dr. Lior Shaltiel?
Dr. Lior Shaltiel is the Chief Executive Officer of NurExone Biologic Inc., leading the company's innovative research initiatives.
What are ExoPTEN's applications?
ExoPTEN is being explored as a treatment for acute spinal cord injuries and other central nervous system conditions.
What prestigious events will NurExone participate in?
NurExone will participate in the Bioprocess International Conference and the Pioneering Israel Medicine Conference.
How effective is ExoPTEN based on studies?
ExoPTEN has shown a significant recovery of motor function in 75% of laboratory rats when administered intranasally.